We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Curis announced preliminary tolerability and PK data from its ongoing Phase 1 dose-finding study of fimepinostat, a small molecule dual inhibitor of PI3K/HDAC and suppressor of MYC ...
James Dentzer has been leading the company’s pre-commercial planning for fimepinostat, which received an FDA fast-track designation in relapsed or refractory diffuse large B-cell lymphoma in May.